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A B S T R A C T
Introduction: Multiple sclerosis (MS) is an autoimmune disease that attacks the central nervous system,
causing the appearance of focal areas of inﬂammation and demyelination. A detailed study of MS would
offer a better understanding of the causes of increased number of MS cases in the Arab Gulf countries.
Materials and Methods: A comprehensive literature search was performed to extract data regarding MS
in general and MS in Arabian Gulf countries in speciﬁc. Only peer-reviewed, full-text articles published
in English were included.
Results: Data have shown a noticeable increase in cases of MS in the Arab Gulf countries. Although the
underlying causes still remain elusive, many factors have been proposed to inﬂuence MS. This review will
discuss the factors inﬂuencing MS, correlate their effects with disease pathology, their interaction in the
context of disease development, and try to explain the increased number of MS in Arabian Gulf countries.
Conclusion: Understanding MS development could open new doors for the treatment of MS, as well as
initiate novel target therapies for citizens of Arab Gulf countries.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Neuroimmunological disorders present a spectrum of diseases that emerge from disrupted interactions between the nervous and the
immune systems. Over the past few years, emerging data have consistently shown an increased number of Multiple Sclerosis (MS) cases
in the Arabian Gulf countries. The Arabian Gulf countries include Kuwait, Bahrain, Oman, Qatar, Saudi Arabia and the United Arab Emir-
ates (U.A.E.). Those countries share common culture, language, waters, atmosphere, and geographical area. An increase in the cases of MS
in those countries could indicate the importance of targeted susceptibility factors. Therefore, the author has chosen to review this disease
in particular and extensively review its susceptibility factors in Arabian Gulf countries.
2. Methods
A comprehensive literature search was conducted to extract data regarding MS. Only peer-reviewed, full-text articles published in English
were included. Keywords and phrases entered onto database browsers include, but not exclusively, multiple sclerosis, multiple sclerosis
reviews, multiple sclerosis in Arabian Gulf countries, multiple sclerosis pathogenesis, multiple sclerosis symptoms, multiple sclerosis clin-
ical subtypes, multiple sclerosis incidence and prevalence, multiple sclerosis causes and multiple sclerosis aetiology, multiple sclerosis
genetic, multiple sclerosis genome-wide study, multiple sclerosis genetic study, multiple sclerosis association study, multiple sclerosis
genetic susceptibility factors, multiple sclerosis epigenetic factors, multiple sclerosis microRNA, multiple sclerosis mitochondrial genome,
multiple sclerosis diagnosis, multiple sclerosis therapy, multiple sclerosis treatment, and multiple sclerosis future. Data were then sub-
tracted according to their signiﬁcance and thoroughly reviewed.
3. Multiple sclerosis (MS)
MS is a chronic, recurrent inﬂammatory disorder of the central nervous system (CNS) with presumed autoimmune aetiology. MS can
be classically deﬁned as a complex, multifactorial, and heterogeneous neuro-immunological disease. Symptoms depend on the anatomical
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locations of demyelinating plaques, though some plaques remain silent without clear measurable symptomatic manifestation. Fatigue and
cognitive dysfunction may be poorly correlated to speciﬁc locations but can be caused by extensive cerebral distribution. MS is usually
manifested by dysfunction of various neurological axes with paresthesia or numbness, motor weakness (particularly in the lower ex-
tremities, resulting in walking diﬃculties), monocular visual disturbances (optic neuritis), incoordination, Diplopia, dizziness, bladder and
sexual dysfunction, sensory symptoms and ataxia [1] and vertigo [2].
4. MS clinical subtypes
Four different subtypes of MS are clinically distinguishable: relapsing remitting MS (RRMS), primary progressive MS (PPMS), second-
ary progressive MS (SPMS), and progressive relapsing MS (PRMS). RRMS represents 85% of MS cases; it is characterised by unpredictable
relapsing episodes, alternating with periods of remission. Moreover, cranial focal areas of inﬂammation and demyelination can be re-
solved overtime, as the damage is reversible. PPMS comprises around 10 to 15% of MS cases, in which steady accumulation of neurological
disability, mainly progressive myelopathy, appears from disease onset. Some patients develop superimposed relapses. These amount to
nearly 5% of MS cases, and are said to display PRMS, which, similarly to PPMS patients, have progressive disability from the onset of symp-
toms, but with acute attacks or relapses. SPMS represents a stage subsequent to RRMS, wherein patients convert from RRMS to SPMS
with time and show progressive neurological decline, either with or without relapses after the initial relapsing remitting pattern. Despite
many prognostic indicators for progression that have been well studied, expectations for patients conversing into SPMS remain diﬃcult
without a deﬁnitive biomarker. A recent study done locally by Alroughani et al. has pointed to few disease progression predictors, of those:
patients’ age at disease onset ≥ 40, male gender, spinal cord symptoms at disease onset, and ≥3 relapses [3]. The neurological disabilities
in SPMS are initially reversible, but intriguingly and for an unknown reason, axonal degeneration occurs with irreversible damages [2,4,5].
The clinical manifestations of MS subtypes may vary between patients, even between those that settle in the same MS clinical subtype.
For example, some patients with RRMS may have mild symptoms and low Expanded Disability Status Scale (EDSS) score and have de-
veloped the disease over a period of more than 20 years, benign MS; others may progress in few years and even develop to SPMS, malignant
MS. Reasons for such variation remain elusive, and long-term clinical results of MS remain challengeable [6].
Neurologists usually assess patient disability by Expanded Disability Status Scale (EDSS). The EDSS was ﬁrst assigned in 1983 by John
F. Kurtzke. The disability is measured in eight functional systems (FS): pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual,
cerebral and others. Score values range from 1.0 to 10.0, with 10.0 equating to death due to MS. Neurologists usually refer EDSS scores of
1.0 to 4.5 to fully ambulatory patients, whereas scores of 5 to 9.5 are assigned to patients with impaired ambulation [7].
5. MS epidemiology
A consideration of MS epidemiology in Arabian Gulf countries must be related to the worldwide number of MS. As for that, the world-
wide epidemiology will be discussed and followed with Arabian Gulf epidemiology.
5.1. MS female to male ratio in general
As it is with other autoimmune diseases, aﬄiction with MS shows a female over male preponderance. The ratio of female:male pa-
tients varies according to each country. In East Asia, for example, this ratio was found to be 3.0, whereas in the United States it equates to
2.6 [2,8]. MS commonly affects adults in their twenties to ﬁfties, peaking at thirty years of age. Sometimes, symptoms ﬁrst present before
the age of 10 or after 60, and in rare cases, on the eighth decade of one’s life [2,8].
5.2. MS incidence and prevalence in general
MS is aﬄicting more people every day. According to the Atlas of MS for 2013, the number of MS diagnoses has increased from 2.1
million in 2008 to 2.3 million in 2013. Moreover, the global median prevalence of MS has increased from 30 to 33 per 100,000 between
2008 and 2013 [8]. However, those numbers may not reﬂect the real number of MS patients as some are not yet diagnosed with MS. This
could be a consequence of either patients being treated for speciﬁc symptoms without exploring the remaining signs of the disease or
the diﬃculty of reaching neurologists.
Ethnicity plays an important role in disease development, seeing that Caucasian populations have 10 times higher prevalence of MS
than do African or Asian counterparts. The highest prevalence has been found in North American and European countries, with a prev-
alence of 140 and 108 per 100,000, respectively; the lowest prevalence, in contrast, has been found in Sub-Saharan Africa and East Asia,
at 2.1 and 2.2 per 100,000, respectively [8–11]. Moreover, within the same population the prevalence could vary according to each country.
In the European population, Sweden harbours the highest prevalence of MS (189/100,000), whereas Albania shows the lowest preva-
lence (22/100,000) [8].
Another element impacting on variation in MS prevalence is regional latitude. In South America, for instance, Argentina, a medium-
risk country for MS, has a prevalence of about 18/100,000. This is six times higher than is the prevalence recorded for Ecuador (3.2/
100,000), a low-risk country for MS [8–12]. Furthermore, in isolated countries, the prevalence of MS could vary between different regions,
as some may provide resistance to MS whilst others do not [13].
5.3. MS incidence, prevalence and regional differences in Arabian Gulf countries
Recent data from the last few years have shown increased cases of MS in the Arabian Gulf countries. Reports from the U.A.E, Dubai in
speciﬁc, indicate an MS prevalence of 54.77/100,000 [95% conﬁdence interval (95% C.I.) = 46.99–62.55] in 2007, with an annual incidence
rate of 6.8/100,000 (95% C.I. = 3.8–9.87) between 2000 and 2007. The female:male ratio was 2.85:1 in Dubai’s native population and the
mean age of onset was 26.66 ± 6.6 years. Patients’ main symptoms were related to motor, sensory, cerebellar and ocular manifestations
(72.78%, 48.41%, 19.96%, 16.13%, respectively), with EDSS median and mean of 1.5 and 2.38, respectively. Patients were diagnosed with
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RRMS (76.9%), SPMS (10.6%), clinically isolated syndrome (CIS) (7.8%) and PRMS (4.4%) [14]. In Kingdom of Saudi Arabia (K.S.A), the prevalence
of MS reached 40/100,000 in 2008, in contrast to 25/100,000 in 1998 [15,16]. Although, no recent registry was found for patients’ diag-
nosis in K.S.A, the 1998 study demonstrated that 60.7% of MS patients have RRMS, 20.2% have PRMS and 19.1% have PPMS. The same study
demonstrated that patients’ mean age at disease onset was 25.9 years, whilst it indicated a 1.32:1 female to male ratio. The main symp-
toms presented in MS patients were the pyramidal symptoms [16,17].
Qatar exhibits a prevalence of 64.57/100,000 (95% C.I. = 58.31–70.37), with a female:male ratio of 1.33:1 and familial history of MS in
10.4% of the patients. Patients’ ﬁrst presented symptoms were sensory, optic neuritis and pyramidal manifestations [18]. The diagnosis
of the patients is as follows: RRMS (58.5%), SPMS (4.5%), PPMS (2%) and CIS (7%) [17]. In the Omani population, the prevalence of MS was
much lower at 4/100,000 between 1990 and 2000, with only 30 patients. The female to male ratio was 0.8:1 and the mean age at disease
onset was 27. Patients’ symptoms mostly covered the visual and motor areas and lesions were found in the optic nerve, spinal cord, ce-
rebral hemispheres and brain stem and cerebellum in 17, 16, 12, 10 patients, respectively. Approximately, one third of the patients showed
optic-spinal form of MS. Surprisingly, only 20% of the patients had positive CSF oligoclonal band results. Diagnosis of the patients is as
follows: RRMS (23 patients), SPMS (4 patients), and PPMS (3 patients) [19,20].
In Kuwait, the prevalence of MS was much higher at 85.05/100,000 (95% C.I. = 82.80–87.04) in 2013 compared to 14.77/100,000 in 2000.
In parallel, the annual incidence rate was 6.88/100,000 (95% C.I. = 5.52–8.55) between 2010 and 2013, compared to 2.62/100,000 in 2000.
The incidence of female and male MS has increased signiﬁcantly to 3.22 and 2.54 folds only between the years 2003 and 2011. More so,
in 2013, the native Kuwaiti population displayed a female:male ratio of 1.8:1 compared to 1.33:1 in 2000. According to the most recent
data, the mean age of disease onset was 35.40 ± 10.99 years, the prevalence peak being between 30 and 39 years [11,21]. Recently, a study
in Kuwait indicated that around 77% of the patients were having RRMS, whilst around 9% of the patients constitute CIS. Relapses per year
was found to be less than 1 in around 52% of the patients, whilst the EDSS score registered 72.8% of patients to have a score of ≤3 and
14.1% of patients to have score of ≥6 [22].
As such and according to Kurtzke’s classiﬁcation system [23], the U.A.E (speciﬁcally Dubai), Saudi Arabia, Qatar, and Kuwait are
considered countries with a high frequency of MS cases (≥30/100,000), whereas Oman is a country with a low frequency of MS cases
(<5/100,000) [23]. This could be a result of the contiguous marriage and the isolated cultures. In Kuwait for example, the governmental
roles minimise foreign marriage to citizens; in AGC, it is not common for citizens to marry foreigners, which could be one of the causes
for enclosing the disease in such community. Also, the increased number of contiguous marriage with the fact that this disease has genetic
factors could explain the increased incidence and prevalence of MS in those regions. Moreover, countries in the AGC are more able to
provide the proper diagnostic tools for MS; moreover, AGC country provides excellent medical care facilities that are free for their citi-
zens. This could results in easier and faster diagnosis of MS. Nevertheless, during the last years, campaigns that streak the awareness of
the community to MS disease have increased the chance of MS early diagnosis. Lastly, new registries for MS are being built, if not initi-
ated already, to assist patient early diagnosis in the AGC.
Diagnosis of MS in the AGC was similar to the international ﬁgures in regard to RRMS clinical subtype; however, in contrast to the
international ﬁgures, PPMS was less prominent in Qatar, Dubai and Kuwait and was second to PRMS and SPMS in K.S.A. and Oman, re-
spectively. The SPMS cases were the second most dominant diagnosis in Dubai and Oman, whilst in Qatar, SPMS cases were the third
most dominant diagnosis clinically. The CIS constituted the second diagnosis in both Kuwait and Qatar, and the third in Dubai. Those data
indicate that internationally and locally, in AGC, RRMS is considered the most diagnosed clinically; however, data regarding the remain-
ing clinical subtypes show regional differences. Those data may indicate patients’ determination to be diagnosed early, a fact that could
be pointed; AGC citizens do not seek medical help in early disease stages, rather, they reach for help in late stages of the disease. Addi-
tionally, physicians’ availability could explain those data; in Kuwait for example, only one specialised hospital for neurological diseases is
available, the Ibn Sina hospital, not excluding some specialised neurological OPD in other hospitals. Appointments, as a consequence, could
take more than a month and patients, as a result, may develop additional brain lesions. Moreover, patients may wait for months to get
MRI appointments in governmental hospitals as a result of the expanded number of patients and low numbers of MRI machine available.
In the end, although the awareness of patients and physicians has increased through the last decades and although the clinical diagnos-
tic criteria are available for MS patients, new specialised hospitals for neurological disease, especially MS disease, must be built to keep
up with the increasing numbers of MS cases.
6. MS pathogenesis
So, knowing that MS has increased in number, an investigation must be performed to track the pathology of MS and identify the phys-
iology of the disease. The CNS is an immune-privileged site with an ability to limit the entry of immune elements, as well as to limit
immune activation to self-components [24,25]. This phenomenon is partially dependent on the properties of the blood–brain barrier (BBB),
which exclusively allows solutes and ions to enter the CNS. The selective entry and exclusion of molecules in the CNS rely on capillary
venules, whereas cell migration takes place in post-capillary venules. Further, this allows migration upon stimulation with chemokines
and cytokines [25].
In case of pathogenic invasion, the innate immune system responds by opsonising and eliminating apoptotic cells. Pathogen-
associated molecular patterns (PAMPs) integral to the pathogenic structure bind cellular receptors and initiate innate immune responses
[26]. Furthermore, the innate immune system recruits adaptive immune cells through secretion of chemokines and cytokines that induce
adhesion molecules on the BBB. This in turn induces the expression of costimulatory molecules on microglia [25].
MS is the main cause of CNS demyelination and severe neurological disability [27]. For reasons still unknown, immune privilege within
the CNS is disrupted in MS patients. Disease pathology primarily surfaces from undesirable activation of antigen-speciﬁc T- and B-cells,
which thereby nucleate a cascade of self-damaging processes that culminate in CNS inﬂammation, demyelination, axonal damage, gliosis
and ﬁnally neurodegeneration. CNS, though, tries to repair itself through remyelination and regeneration mechanisms. However, such pro-
cesses will continuously be interrupted by the recurrent MS attack [28–30].
Though it is unknown what causes T cell activation, it is a common fact that such activation takes place in the lymph node. One theory
indicates peripheral T cell activation, then, re-circulation to the CNS by sphingosine 1-phosphate (S1P) gradient, which has a high aﬃnity
to the sphingosine 1-phosphate receptor subtype 1 (S1P1) expressed on T cells. At ﬁrst, the T cells that enter the lymph node decrease
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their S1P1 levels to allow T cells activation, then after activation and clonal expansion, the levels of S1P1 increase to allow T cells to return
to circulation. The levels of S1P are higher in body ﬂuids and tissue than in lymphoid tissues. The gradient of S1P will drive the T cell
from the lymphoid tissue into the blood. Through the same concept, the T cells could be driven into CNS [30]. One of the approved MS
drugs, Fingolimod, exerts its action through the blockage of S1P1 receptors [31]. The action of this drug in reducing inﬂammation in clin-
ical trials may prove the importance of S1P1 receptors in disease activation in the CNS. The other theory postulates T cells activation at
the CNS and peripheral T cells activation to be a consequence.
Through the activated endothelium, T activated cells make an entry into the CNS. There the T cells releases the immunoregulatory mol-
ecules of cytokines, chemokines and histocompatibility antigens. Demyelination, then, would be the result of either antigen-speciﬁc
immunoreactions or a non-speciﬁc reaction due to immunoregulatory molecules release. Several hypotheses, thus, have postulated the de-
myelination process in MS; of those, the receptor-mediated phagocytosis of myelin, myelin stripping, vesicular disruption of myelin sheaths
and drying back oligodendrogliopathy. The ﬁrst hypothesis indicates interaction between opsonised myelin and Fc and complement recep-
tors of the macrophages, which results in their phagocytosis. In the second hypothesis, lymphocytes andmacrophages invade myelin sheaths,
causing appearance of lesions. The third hypothesis claims that myelin sheaths undergo a vesicular transformation that results in severe de-
structive lesions. The fourth hypothesis goes to pathological alteration in the most distal extension of oligodendroglia cell processes and this
in turn may result in demyelination. During active stages of MS, oligodendrocytes will be dramatically lost due to additional immune-
mediated mechanisms; however, large numbers of undifferentiated oligodendrocyte progenitors will be recruited in the site of plaques. Some
oligodendrocytes may survive initial destruction in the active stages, but those cells do not function effectively [32].
In the case of direct attack against myelin sheath mediated by active T-cells, demyelinated sites would rapidly remyelinate and some
oligodendrocytes are spared from destruction. This mechanism is directed by either immunotoxins or antibodies that act directly with
activated T-cells. The best known antibody is the myelin oligodendrocyte glycoprotein (MOG), which is expressed on the myelin sheath
and oligodendrocytes processes. In some cases, severe demyelination may occur with complete loss of oligodendrocytes and lack of
remyelination. Those cases may result from pathological mechanisms that effectively destroy all oligodendrocytes with their progenitors,
due to defect in the oligodendrocytes’ progenitors or antigen-mediated immune response against those cells. In cases of attempts of
remyelination, some stressed oligodendrocytes may be in relative risk of destruction, leading to gradient oligodendrocytes loss from the
active lesion edge into the centre of the plaques. In such cases, gamma/delta T cells are thought to react and lyse oligodendrocytes by the
help of stress proteins, such as hsp65 or alpha B crystallin. In another opinion, gradient oligodendrocytes loss may result from insuﬃ-
cient growth factors (GF) and such lack of GF may result in apoptosis. Cases with oligodendrocytes death in periplaque white matter outside
the zone of active demyelination may be caused by viral infections, toxins, or dysregulation of microglia or macrophages. In those cases,
the primary oligodendrocyte destructions may result in secondary oligodendrocyte destructions [32].
Mostly, patients suffer episodic disorders and, with time, they develop to progressive phases of the disease. Two overlapping causes of
MS have been proposed: inﬂammation and neurodegeneration. The former is responsible for the relapsing–remitting phases of the disease,
whereas demyelination and axonal loss (neurodegeneration) are responsible for progressive symptoms [27].
7. MS aetiology
The aetiology of MS remains elusive; however, several factors have been proposed to inﬂuence its development, namely, environmen-
tal, immunological, and genetics. This review will shed light on MS aetiology and identify its relations to Arabian Gulf countries’ increased
MS cases.
7.1. Environmental and immunological susceptibility factors
Environmental and immunological factors have always been associated with MS, of which vitamin D deﬁciency, ultraviolet irradia-
tion, viruses, smoking, obesity, and alcohol consumption attract the most attention.
7.1.1. Vitamin D
Vitamin D, also known as D2 or D3, acts essentially as a hormone, and functions in endocrine, paracrine, and intracrine signalling. D2,
also termed ergocalciferol, is a synthetic product of the plant sterol irradiation, whereas D3 (cholecalciferol) is a pro-hormone produced
in the skin after ultraviolet B (UVB) irradiation on a cholesterol precursor, 7-dehydrocholesterol. Upon skin absorption of UVB irradiation,
7-dehydrocholesterol is enzymatically converted to pre-vitamin D3, which in turn undergoes thermal transformation into vitamin D3. Only
a small amount of vitamin D3 comes from dietary intake (e.g. fatty ﬁsh, eggs, and fortiﬁed foods) [33].
In the liver, vitamin D3 is metabolised by 25-hydroxylase to 25-hydroxyvitamin D3 (25(OH)D3), a pre-hormone; afterwards, the kidney
hydroxylates 25(OH)D3, thereby converting it to 1, 25-dihydroxyvitamin D3 (1,25(OH)2D3) to enter the endocrine pathway. 1, 25(OH)2D3
circulates in the blood as a hormone that regulates mineral and skeletal homeostasis. Whilst the endocrine pathway takes action in the
kidney, the paracrine–intracrine pathway ensues in various end-organ tissues, such as the prostate gland, breasts, colon, lungs, and keratinocytes.
In the paracrine–intracrine pathway, 25(OH)D3 is converted to 1,25(OH)2D3 intracellularly by 25(OH)D3 1-a-hydroxylase, a calcium-
independent process. 1, 25(OH)2D3 has a short half-life of approximately 4 to 15 hours. In contrast, 25(OH)D3 has a longer half life of around
15 days, which makes it a better indicator of vitamin D status. Vitamin D, or its end product 1, 25(OH)2D3, contributes to different body
haemostatic processes, including cell regulation, growth, and differentiation; metabolic functions; bone density and health; neuromus-
cular functionality; and immunomodulation [33].
Vitamin D receptors (VDR) are predominantly expressed in T-cells (more so in CD8+ cells than in CD4+ cells) and in B-cells. In these
cells, vitamin D down-regulates differentiation of monocytes into dendritic cells (DCs) and differentiation and proliferation of DCs. Con-
sequently, this decreases T-cell stimulation, controls T-cell activation, and inhibits T-cell proliferation. Moreover, it reduces the production
of interleukin (IL)-2 (a vital growth factor for T-cells), suppresses production of pro-inﬂammatory Th1 cell-derived IFNγ and tumour ne-
crosis factor α (TNFα), and reduces pro-inﬂammatory Th17 cell activity and IL-17 production. Additionally, it enhances the secretion of
the anti-inﬂammatory cytokine IL-10. Importantly, vitamin D up-regulates the development of regulatory T cells (Tregs) expressing cy-
totoxic T-lymphocyte antigen 4 (CTLA-4) and the master transcription factor forkhead box P3 (foxbp3) [34].
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These receptor-mediated signal transduction cascades all amalgamate in an overall anti-inﬂammatory effect. In particular, a protec-
tive Th2-type phenotype is conferred upon CD4+ T-cells, and the differentiation of B-cells is additionally inhibited. Through downregulation
of DC, Th1, Th17, and B-cell proliferation and pro-inﬂammatory cytokine production, and through upregulation of Th2 and Treg cell pro-
liferation and anti-inﬂammatory cytokine production, it is evident that vitamin D exhibits immunomodulatory, pro-resolving, and anti-
inﬂammatory properties. As such, it is not unreasonable to surmise that vitamin D deﬁciency signiﬁcantly impacts the pathophysiology
of autoimmune diseases, to which MS is not an exception [34].
Studies have been performed to assess the effect of vitamin D deﬁciency on MS development. Some of these studies have suggested
that vitamin D protects people from MS [35]. Others, on the other hand, have rebuffed a protective role for vitamin D in MS disease de-
velopment [36].
In a study conducted on 49 MS patients with a mean duration of 7.8 years, patients were assigned vitamin D3 supplements for 52 weeks.
25 patients were treated with vitamin D, whilst 24 patients acted as controls (mean age = 40.5 years, EDSS = 1.34, and 25(OH)D = 78 nmol/l).
On the ﬁrst 28 weeks, vitamin D supplements were up to 40,000 IU/day, aiming to raise serum 25-hydroxyvitamin D (25(OH)D) rapidly,
followed by 12 weeks of 10,000 IU/day supplements, and ﬁnished with 12 weeks of 0 IU/day supplementation. Additionally, 1200 mg of
calcium were administrated daily throughout the trial. 41.1% of the patients had decreased relapses in the test group, whilst 16.7% had
decreased relapses in the control group (no vitamin D3) when compared with data from the prior year (P = 0.17 for the difference between
groups). The proportion was insigniﬁcant for vitamin D3 intake, demonstrating that vitamin D3 could have a role in MS progression; however,
a larger study pool needs to detect such function [37].
A larger pooled study was conducted on 799 randomised MS patients, of which 465 had at least one serum 25(OH)D3 measurement,
417 with two or more, 396 with three or more, and 303 with all four 6-, 12-, and 24-month (seasonally asynchronous) measurements.
Samples with minimum 2ml serum were used for analysis. Patients were checked on every ﬁve years clinically and by magnetic reso-
nance imaging. Accordingly, the patients had reduced MS activity and slower progression rate with higher 25(OH)D3 levels. Average serum
25(OH)D3 levels of 20 ng/ml within the ﬁrst 12 months indicated a 57% lower rate of new active lesions (P < 0.001), 57% lower relapse
rate (P = 0.03), 25% lower yearly increase in T2 lesion volume (P < 0.001), and 0.41% lower yearly loss in brain volume (P = 0.07). Even more,
associations were found between 25(OH)D3 levels measured up to 12 months and MS activity or progression in the following 24 to 60
months. Moreover, serum 25(OH)D3 levels ≥ 20 ng/ml at up to 12 months predicted lower disability [EDSS, −0.17; P = 0.004] during the
subsequent four years [38].
Likewise, the University of California at San Francisco has reported through the EPIC program that with each 10 ng/ml increase of 25(OH)D3,
measured in patients’ plasma, the percentage of T2 lesion and gadolinium-enhancing lesion decreases by 15% and 32%, respectively, con-
current with disability reduction (−0.047; 95% C.I. = −0.091 to −0.003; P = 0.037). The EPIC program is a ﬁve years MS cohort study that
entails patients’ evaluation annually, through clinical, MRI and laboratory data. Participating White patients had ages of 18 to 70, and had
EDSS score less than 8.0. Patients were clinically diagnosed as CIS or RRMS and had at least one follow-up or had completed two year
follow-ups after blood sample collection [39].
However, in a recent meta-analysis conducted on 66 articles, no association was found between patients treated with vitamin D and
risk of MS relapses. The study, despite that, had some methodological limitations related to relapsing rate and duration, vitamin D re-
lapses target levels and dose and formulation of vitamin D. In conclusion, the authors have indicated the importance of future larger and
prolonged studies to address the real risk of vitamin D [40].
7.1.1.1. Vitamin D induction points in MS. In a recent investigation designed to assay the effects of 1,25(OH)2D3 on TH cells during their mi-
gration from the lymph nodes to the CNS, myelin-reactive TH cells were successfully generated in the presence of 1,25(OH)2D3. Furthermore,
they secreted pro-inﬂammatory cytokines and did not preferentially differentiate into suppressor T-cells. The cells were able to leave the
lymph nodes, enter the peripheral circulation, and migrate to subcutaneous (s.c.) immunisation sites. Conversely, mice TH cells were unable
to migrate to the CNS when treated with 1,25(OH)2D3; they were maintained in the periphery. However, at the end of the treatment period,
the mice rapidly developed experimental autoimmune encephalomyelitis (EAE), which suggests that 1,25(OH)2D3 halts the disease tem-
porarily via inhibiting TH cell migration to the CNS [41].
These facts are consistent with previous studies detailing a major effect for vitamin D supplementation on increased production of
serum transforming growth factor β1 (TGFβ1), a T-cell inhibitory cytokine secreted by different types of cell, including Tregs [42]. More-
over, supplementation of MS patients with vitamin D was able to inhibit in vitro T-cell proliferation and the development of IL-6- and
IL-17-producing cells, as well as enhance IL-10 production and Treg proliferation [43]. Even more, vitamin D could stimulate CD46 and
IL-10, which contribute to anti-inﬂammatory action [44].
Other studies have shown that the vitamin D/vitamin D receptor (VDR) complex regulates the transcription factor of the HLA-
DRB1*15 allele, the main genetic risk factor for MS susceptibility in Caucasians, in addition to other non-HLA MS susceptibility genes.
The regulation of these genes is mediated through binding of the VDR to a conserved vitamin D response element (VDRE) near the pro-
moter region [45–48]. Thereby, vitamin D exerts its effect on the development of MS indirectly through interaction with susceptibility
loci.
7.1.1.2. MS susceptibility loci in Vitamin D genes. As vitamin D exerts a major effect on MS, several studies have turned to the genetics of
the enzymes involved in the vitamin D signalling pathway [45,49–53]. Agliardi and colleagues succeeded to ﬁnd single nucleotide poly-
morphisms (SNP) in the TaqI region of the VDR gene (rs731236) that demonstrate correlation with MS (P = 0.004, OR = 0.53) [45]. A year
later, Cox and colleagues replicated the analysis on two SNPs in the VDR gene (TaqI SNP rs731236 and FokI SNP rs2228570) and found a
weak evidence of potential association of the rs731236 with MS [49]. However, they found that the active form of FokI SNP rs2228570
was highly dependent on the genotype of HLA-DRB1*15:01, which supports earlier ﬁndings of Cox et al. and Orton and colleagues [49,52,53].
On the other hand, other markers within the VDR, including 1-alpha-hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1), cytochrome P450
2R1 (CYP2R1) and vitamin D binding protein (DBP), failed to provide any signiﬁcant association with MS [50–53].
7.1.1.3. Vitamin D across Arabian Gulf populations. Sun-derived ultraviolet irradiation (UVR) is the main catalyst of bodily vitamin D3 syn-
thesis, hence explaining why the European white population shows increased susceptibility to MS. White European populations are less
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frequently exposed to sunlight as a result of long winter months [5,27,54]. In Arabian Gulf countries, despite the sunny climate, vitamin
D deﬁciency remains a critical health concern. Saudi Arabia, the UAE, Oman, Bahrain, Qatar, and even Kuwait have reported severe vitamin
D deﬁciency in their inhabitants.
A study in King Abdulaziz Medical City (KAMC) in Riyadh, K.S.A, has shown that 78.1% of females and 72.4% of males in a cohort of
3475 out-patients had vitamin D deﬁciency [15,55]. In another study conducted in Jeddah, K.S.A, around 13.72% of the study group had
normal vitamin D levels (20–70 ng/ml), 58.82% had relative vitamin D deﬁciency (<20 ng/ml), and 27.46% had severe vitamin D deﬁcien-
cy (<7 ng/ml) [56].
In the UAE, results have similarly shown vitamin D deﬁciency and insuﬃciency amongst healthy adolescents between the ages of 15
and 18 (19.7% had serum levels ≤ 15 ng/ml, and 45.4% had serum levels ≤20 ng/ml) [57]. More intriguingly, deﬁciency was reported in
university students in particular when vitamin D serum levels were assayed at Abu Dhabi. Tests performed on 138 females and 70 males
revealed vitamin D concentrations of 20.9 ± 14.9 nmol/l in the former, and 27.3 ± 15.7 nmol/l in the latter [58].
The “2004 Oman National Micronutrients Survey” highlighted the prevalence of vitamin D insuﬃciency amongst healthy Omani females
of childbearing age, as well as pregnant women [59]. Similarly, the Bahraini population reported vitamin D deﬁciency in 49.4% of 500
healthy volunteers attending the blood bank in Bahrain [60].
In Qatar, a study conducted in primary healthcare clinics communicated that vitamin D deﬁciency prevails in 61.6% of Qatari adoles-
cents aged 11 to 16, 28.9% of Qatari children aged 5 to 10, and 9.5% of children below ﬁve years of age. Evidently, vitamin D deﬁciency
seems to increase from childhood through adolescence, a phenomenon that may be attributable to lifestyle changes [61]. In a separate
study conducted on healthcare professionals working at Hamad Medical Corporation in Doha, Qatar, around 340 healthy volunteers were
recruited. Of these, 87% had vitamin D levels < 20 ng/ml [62]. Further, of the 93 male Middle Eastern athletes presenting in the Qatar Or-
thopaedic and Sports Medicine Hospital (Doha, Qatar), 90% had serum vitamin D concentrations <20 ng/ml [63].
In the Kuwaiti population, 300 volunteers were randomly analysed for vitamin D levels, all of whom were age- and sex-matched with
similar skin phototypes. 150 of these had been applying sunscreen products for at least two years, whereas the remaining 150 never used
sunscreen products in their life. Both groups suffered vitamin D deﬁciency, and statistical comparison was insigniﬁcant (60.67% vs 54.67%;
P > 0.001) [64]. In another study, more than 80% of Kuwait’s population had vitamin D deﬁciency [65].
To summarise, one can establish that Arabian Gulf countries report low vitamin D levels, and that vitamin D could contribute to the
increasing number of MS cases in the last few years. Vitamin D deﬁciency in this region may stem from a lifestyle based on technology,
sedentary activity, lack of exposure to sunlight, and unhealthy dietary patterns, all of which could be addressed to curtail regional cases
of MS [66].
Although vitamin D seems to show a good correlation with MS, one could not exclude the thought that vitamin D deﬁciency could be
a consequence of MS rather than a risk factor, as most studies have been conducted after the disease diagnosis and no record of vitamin
D levels appear from the early childhood of the patient. Moreover, studies have shown conﬂicting results about the effect of vitamin D on
MS disease, some indicating patients’ recovery, others pointed to patients’ relapses, whilst some had no signiﬁcant association between
vitamin D and MS disease. Nevertheless, vitamin D has been reported to be deﬁcient even in healthy individuals, which may state that
this deﬁciency is irrelevant to MS. In conclusion, vitamin D levels should be taken into account with patient history, medication and genetic
factor.
7.1.2. Ultraviolet light
Low exposure to UVR is thought to be another factor that increases susceptibility to MS. UVR acts on the human body through several
mechanisms, either vitamin D-dependent or vitamin D-independent. In the skin, UVR acts on the cholesterol precursor, 7-dehydrocholesterol,
and catalyses the formation of pre-vitamin D3, which in turn undergoes thermal transformation into vitamin D3 [33]. Vitamin D, as pre-
viously explained, has a major role in immunomodulation [34]. One exemplary function is the activation of the cathelicidin family of proteins
[67].
It is thought that exposure of skin to UVR, followed by the application of a normally sensitising antigen, results in tolerance induction
to the antigen [68]. This tolerance could be mediated by a cathelicidin termed LL-37. LL-37 consists of a C-terminal cationic domain and
an N-terminal cathelin portion of the holoprotein. The C-terminal cationic domain functions in antimicrobial activity, and is activated only
when unchained from the N-terminal domain. In addition, LL-37 is implicated in different body functions, including the inﬂammatory
response, cytokine release, cell migration, and lipopolysaccharide neutralisation. Moreover, LL-37 downregulates the expression of mono-
cyte Toll-like receptors (TLRs); the latter induces inﬂammation and triggers sepsis and autoimmune disease exacerbation. The induction
of LL-37 is believed to be mediated by vitamin D-dependent activation of the cathelicidin antimicrobial peptide (CAMP) gene [67].
Not only does UVR mediate vitamin D production, but it can also induce prostaglandin E2 (PGE2) and cis-urocanic acid synthesis. Upon
induction, PGE2 binds to prostaglandin E receptor subtype 4, thereby signalling an increased receptor activator of NF-κB ligand (RANKL)
expression in the epidermis and an elevated inﬂux of Treg cells into the draining lymph nodes [69].
UVR converts trans-urocanic acid to the cis conﬁguration. The latter in turn stimulates production of reactive oxygen species (ROS) in
keratinocytes, thereupon commencing oxidative DNA damage and immunosuppression. More so, cis-urocanic acid modulates the pro-
duction of immunosuppressive molecules from keratinocytes, nerve cells, and mast cells [69]. In a recent study, cis-urocanic acid levels
were assayed to estimate UVR intensity on MS patients. Levels were signiﬁcantly lower in MS patients in contrast to the case with con-
trols. Moreover, when myelin basic protein (MBP)- and Myelin Oligodendrocyte Glycoprotein (MOG)-speciﬁc T-cells, peripheral blood
mononucleated cells (PBMCs), and DCs were stimulated with cis-urocanic acid, a signiﬁcant increase in IL-10 and a decrease in IFN-γ pro-
ductionwere reported. Concomitantly, therewas amarked increase in CD4+CD25+FoxP3+ Treg cell percentages and reduced antigen presentation
capacity. Additionally, after cis-urocanic acid-mediated activation of the 5-HT2A receptor, an increase in phosphorylated forms of ERK
1/2 and JNK2 was noticed [70].
EAE models have further proven the effect of vitamin D-independent pathways for UVR on MS susceptibility. UVR exposure in these
models suppressed MS development independently of vitamin D. Moreover, the observable suppression occurred with only a modest,
transient increase in serum vitamin D levels; this was inadequate to suppress EAE independently of UVR treatment [71].
Higher exposure to UVR in early ages (6–15 years) was also found to decrease the risk of MS development, especially in winter months.
That is, a dose–response relationship has been observed [72]. Interestingly, increased exposure of monozygotic twins to sunlight during
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childhood decreased their risk of developing MS. Patients who spent more time during their childhood tanning under the sun had a lower
risk (OR = 0.40, 95% C.I. = 0.19 to 0.83) [73].
In Newfoundland, Canada, a protective role for UVR was established in MS and appeared to be strongest in the ﬁrst ten years of life
[74]. In another study, MS-based mortality seemed to decrease with occupational exposure to UV light [75]. Similarly, in the US, expo-
sure to UVR was highly protective against MS. Moreover, when comparing North American regions with lowest and highest UVR, the lowest
UVR had greater relative risk (RR) ratio for MS (RR = 3.78), in contrast to the highest UVR (RR = 1.52) [76]. Additionally, region of birth
and maternal exposure to UVR in the ﬁrst trimester were independently associated with the risk of MS in offspring in Australia [77]. More-
over, in France and England, data revealed an association between annual mean ultraviolet radiation B (UVB) and MS prevalence, further
supporting a role for sunlight exposure on MS risk [52,53,78]. Furthermore, data from France have provided a possible role for gender-
speciﬁc effects of UVB exposure [52,53]. Meanwhile, results from England highlighted a possible correlation between UVB and Epstein–
Barr virus (EBV) infection in disease development, but exact pathology has yet to be uncovered [78]. Seasons and solar cycles were further
factors indicated to have some inﬂuence on MS susceptibility in four different populations: Italian, Danish, White American, and African
American [79]. Still, another factor could be the patient’s month of birth [80,81].
In an interesting study conducted simultaneously in Norway and Italy, 1660 MS patients and 3050 controls showed signiﬁcant asso-
ciation between infrequent summer outdoor activity and increasedMS risk after reporting their sun habits during childhood and adolescence.
The strongest association was found between ages 16 and 18 in Norway [odds ratio (OR) = 1.83, 95% C.I. = 1.30–2.59], and between birth
and age 5 in Italy (OR = 1.56, 95% C.I. = 1.16–2.10). Moreover, a strong association was found between winter and increased risk of MS
(OR= 1.42, 95% C.I. = 1.03–1.97). More so, the frequency of utilising sunscreen between birth and the age of 6 was associated with MS in
Norway (OR = 1.44, 95% C.I. = 1.08–1.93) after adjusting for outdoor activity during the same period. Additionally, people with red or blonde
hair were more associated with MS after adjusting for outdoor activity and sunscreen use (OR = 1.67, 95% C.I. = 1.06–2.63 and OR = 1.36,
95% C.I. = 1.09–1.70, respectively) [82]. These data have further indicated the effect of UVR on MS susceptibility.
In an entirely contradictory investigation (the Woolmore study), no association whatsoever was documented between UVR exposure
and MS risk. In the said study, a questionnaire was distributed amongst 448 Caucasians with MS in the UK. When tested, parameters like
skin type and UVR exposure during childhood (0–16 years) and early adult life (17–40 years) failed to provide any correlation [83]. Other
variables, including seasonal ﬂuctuations in UV-light, also did not correlate with MS; this was especially assessed in 11,415 MS patients
in 36 centres across 15 different countries [84]. Moreover, Araki and colleagues failed to show any signiﬁcance for UVR on Japanese MS
patients, and proposed other factors that may affect MS susceptibility, such as the month of birth [85].
In summary, UVR has varying effects on MS susceptibility, either through vitamin D-dependent or vitamin D-independent pathways.
Many studies have shown the effect of low exposure of UVR on MS susceptibility; however, few have ruled out the UVR effect on MS.
Further studies must be carried out to investigate UVR with MS susceptibility.
7.1.3. Viral infections
Viral infections have also been associated with MS susceptibility. Several viruses have been proposed, the most common being measles
virus, rubella virus, Varicella-Zoster, Epstein–Barr Virus (EBV), and mumps virus. However, epidemiological and laboratory studies have
particularly demonstrated importance of EBV in disease susceptibility. Observation of EBV oligoclonal immunoglobulin in the cerebro-
spinal ﬂuid (CSF) of MS patients has supported the involvement of EBV in disease susceptibility. EBV travels to the brain through B-cells,
which inﬁltrate the white matter of progressive MS cases. EBV drives clonal expansion and maturation of B-cells in the brain, establish-
ing chronic infection. Periodic reactivation of the virus could result in the activation of inﬂammatory disease activity in the brain and tissue
damage as a result of CD8+ T-cell cytotoxicity response to EBV. The presence of memory B-cells and the homology between the penta-
peptide sequence of EBV nuclear antigen and the MBP epitope causes subsequent induction of immune response to the myelin sheath,
causing axonal demyelination. Furthermore, EBV expresses a surface protein, alpha-B crystalline, which is an abnormally expressed autoantigen
on the MS patient’s brain [2,5,27]. Moreover, patients infected with EBV have higher propensities to develop MS contrasted to normal
individuals, the difference being 15-fold amongst children and 30-fold amongst adults [35].
Although not much study was found on the incidence of EBV in the AGC, interestingly, one study found a 43% of the U.A.E patients’
tonsils specimens and 15% of adenoids specimens to be infected with EBV [86], a fact that could relate to increased MS incidence in the
U.A.E. In another study conducted on 141 Kuwaiti MS patients, signiﬁcant elevation of EBV antibody titres (anti-EBNA1, p = 0.008; anti-
VCA, p = 0.028) was found, in contrast to the 40 healthy controls. Moreover, the study demonstrated that male patients had higher anti-
EBNA1 titres than male controls (p = 0.005) and female patients (p = 0.03) [87]. Such studies could point to the risk of EBV virus in MS
pathogenesis; however, further studies must be done to prove such claim in AGC.
7.1.4. Smoking
Smoking has also been linked to around 50% increased risk of developing MS in case–control studies [2,5,27,88]. In the 1960s, ciga-
rette smoking was identiﬁed as a susceptibility factor in MS, and several papers have since been published to establish the effect of smoking
on MS [89]. An Isrealian study in 1965 detailed that 44% of MS patients had smoked before clinical MS onset (P = 0.02) [90]. The Oxford
Family Planning Association (Oxford-FPA) study in 1993 found smoking to be signiﬁcantly associated with MS [91]. A British study per-
formed by the Royal College of General Practitioners showed hints of a dose–response effect with relative risks associated with future
MS development. These were 1.2 for smokers of 1–14 cigarettes/day, and 1.4 for smokers of ≥15 cigarettes/day [92]. Similarly, a Canadian
study in 2001 showed a dose–response equating to 0.7 for 0–10 cigarettes/day, and up to 5.5 for >40 cigarettes/day [93]. Similarly, in 2007
Pekmezovic and colleagues recognised the presence of a dose–response relationship between the risk of MS and both duration (in years)
of smoking (P = 0.027) and number of cigarettes smoked daily (P = 0.021) [94].
In Canada and Denmark, the tendency to develop MS increases by a factor of 1.5 in continuous smokers as opposed to people who
have never smoked [95]. Similarly, the Swedish relative risk for developing MS has been increased by a smoking habit [96,97]. Iranian
people also showed an increased risk for developing MS with cigarette smoking (OR = 2.67; 95% C.I. = 1.70–4.21; P <0.001). Whereas past
smokers had a risk factor of 8.83 to develop MS (P < 0.001), current smokers have a risk factor of 1.84 (P = 0.021) [98]. In a similar study,
another group in Iran was able to replicate these data, wherein the risk of developing MS was 1.78 (P = 0.03) [99].
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In 2011, a meta-analysis of 14 articles covering MS risk with cigarrette smoking proved the existence of an association between cig-
arette smoking andMS [RR = 1.48, 95% C.I. = 1.35–1.63, P < 10−15] [100]. Evenmore intriguing was the ﬁnding that passive smoking is associated
with increased susceptibility to MS (OR = 1.3, 95% C.I. = 1.1–1.6), as increased exposure duration correlates with increased risk (P = 0.003)
[101,102]. This trend was also corroborated in the case of exposure to parental smoking (RR = 2.18), where the duration of exposure affects
the level of risk (RR = 2.49) [103].
Likewise, an association was observed between cotinine (a nicotine metabolite) levels ≥10 ng/ml, and increased risk of MS; however,
this was only prominent in young patients below a median age of 26.4 years (OR = 2.2, 95% C.I. = 1.3–3.8) [104,105].
Aside from such an association, smoking was more signiﬁcantly tied to ﬁrst clinical demyelinating event (FCD) (AOR = 1.89, 95% C.I. = 1.82–
3.52) [106]. Further, smoking has been associated with an increased risk of transforming a relapsing–remitting clinical course into a secondary
progressive course [107–110]. Also, it increases the risk of transforming from a clinically isolated syndrome into clinically deﬁnite MS
(OR= 1.8, 95% C.I. = 1.2–2.8) compared with non-smokers (P = 0.008) [111]. More so, compared to non-smoking MS patients, in smokers,
smoking worsens the progression, severity score, and brain parenchymal fraction; increases the EDSS score; and increases brain lesions’
volume and brain atrophy [88,108,109,112–114].
Critically, smokers have a higher chance of major mobility requirements (90% higher) compared to individuals who had never smoked.
Patients who have a longer duration of smoking cessation have reduced disease activity. Moreover, smoking patients have a signiﬁcantly
lower health-related quality of life (HRQOL) than non-smokers or former smokers. Heavier smoking paralleled a much greater impair-
ment of HRQOL [115]. Similarly, in a study whose main aimwas irrelevant to smoking, a crucial secondary ﬁnding was documented: smoking
is associated with increased MS disability (p < 0.001) [116].
7.1.4.1. Smoking induction points in MS. In contrast to popular theory, nicotine is not the inﬂuencing product in this pathway. The Swedish
snuff, a tobacco product that provides users with a nicotine dose comparable to cigarette smoking, was shown to be unassociated with
MS, thus indicating a nicotine-free induction pathway [117,118].
An alternative elucidation takes into acount the effect of tobacco smoke on the innate and adaptive immune responses, which could
consequently modulate autoimmunity [88,119]. In Lewis rats, upon exposure to cigarette smoke, inﬂammation and pro-oxidant markers
start to develop in the brain. Th1, Th17 and Treg cell-associated cytokine responses commence. MHC class II, which is expressed by ac-
tivated astrocytes as well as by inﬂammatory cells, is also upregulated in this case. Interestingly, though, TNF-α, a cytokine that is normally
expressed in activated astrocytes, is not expressed in brain tissues. Furthermore, Nrf2, an oxidative stress-induced transcription factor
that regulates the expression of a number of antioxidant genes, is also elevated in the rats’ brains. As such, these observations indicate
that cigarette smoke triggers antioxidant responses that occur as a result of cellular stress [120].
In one study conducted on 106 families with a history of MS, a correlation between smoking and genetic susceptibility to MS was ruled
out [101,102,121]. In 2011, however, Hedström and colleagues established that the presence of HLA-DRB1*15 and the absence of HLA-
A*02 increase the risk of MS in smoking patients compared to non-smoking patients who do not express these particular genetic markers
(OR = 13.5, 95% C.I. = 8.1–22.6). Moreover, smokers expressing a different genotype had a risk of 1.4, whereas non-smokers expressing this
genotype had a risk of 4.9. All in all, their study suggests that smoking inﬂuences genetic traits in developing MS [101,102]. However,
Sawcer and Hellenthal have established that such a study is very hard to be reliable due to extensive circumstances. But they hoped in
the next few years we could develop a reliable study that could integrate the effect of gene-environment on the disease development
[122].
A recently identiﬁed, perplexing interaction was found between smoking and EBV infection, wherein the two factors act in concert to
predispose one to MS at a young age, but offer protection at an older age. Undeniably, this phenomenon awaits much further investiga-
tion [104,105].
Yet another mechanism by which smoking can inﬂuence the course of MS is through the induction of neutralising antibodies against
interferon β-1a (IFNβ1), a drug administrated to MS patients (OR = 1.9; 95% C.I. = 1.3–2.8; P = 0.002) [96,97]. Also, anti-natalizumab anti-
bodies (natalizumab, another drug used for MS cases) were found to be in great risk of development in MS smoking patients compared
to non-smokers (OR = 2.4, 95% C.I. = 1.2–4.4), with higher risk being observed in higher intensity smokers [96,97].
7.1.4.2. Smoking in Arab Gulf countries. According to Abu Dhabi’s Pre-marital Screening Program, 2011, almost 24.7% of the population
are current smokers [123].
Kuwaiti military have also indicated that 41% of their personnel stationed in Kuwait during summer to autumn of 2012 are current
users of tobacco products during the deployment [124]. Even more, the prevalence of smoking amongst students of health sciences in
Kuwait was surprisingly 31% amongst all males and 3% amongst all females [125].
In K.S.A., the number of smokers constantly increases between adolescent students [126]. Those facts were all indicators of genera-
tions’ abusive tobacco smoking habit which could be the hidden cause of increased MS cases in the Arabian Gulf countries.
7.1.5. Obesity
Obesity is an alarming disorder that greatly impacts on one’s health and life expectancy. Countless diseases are exacerbated in the
context of obesity; MS is no exception. Data collected from women in the Nurses’ Health Study I (n = 121,700) and II (n = 116,671) show
that obesity at the age of 18 [body mass index (BMI) ≥ 30 kg/m2] is associated with an increased risk of developing MS (RR = 2.25, 95%
C.I. = 1.50–3.37,P-trend<0.001).Moreover, largebody size at age20wasassociatedwith a96% increased riskofMS induction (95%C.I. = 1.33–2.89,
P-trend = 0.009); however, no signiﬁcant association was established between adult body mass and MS risk [127]. In one Swedish case-
control study, a risk was proven for the development of MS concurrent with obesity. Subjects whose BMI exceeded 27 kg/m2 at age 20 had
a two-fold increased risk of developing MS compared with normal subjects [128]. In particular, 302,043 individuals from the Copenhagen
School Health Records Register (CSHRR) were screened to assign the BMI at ages 7 to 13. At each one-unit increase in the BMI z-score, an
increase in the risk of MS by HR = 1.17 (at age-7) and HR = 1.15 (at age-13) was found [129].
7.1.5.1. Obesity induction points in MS. Three theories have been proposed to explain the effect of obesity on MS. To begin with, the ﬁrst
theory advocates a role for adiponectin. The latter is an adipocyte (fat cell)-derived adipokine (type of cytokine) that displays anti-inﬂammatory
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properties and circulates in the blood at very high concentrations [130,131]. Moreover, adiponectin shows a protective effect on obesity
development [132]. Unlike other adipokines, the secretion and circulating levels of adiponectin are inversely proportional to body fat content
[131].
A 2013 investigation was conducted in animal models to assay the effect of adiponectin deﬁciency in obese MS patients. The readouts
included in the study were cytokine levels, lymphocyte productivity and functionality, and Treg cell number in spleen and the CNS. In a
model of EAE, adiponectin-deﬁcient (ADPKO) mice showed greater CNS inﬂammation, demyelination, and axon injury. Particularly, ADPKO-
EAEmice show excessive lymphocyte proliferation and secretion of IFN-γ, IL-17, TNF-α, and IL-6 comparedwith wild-type EAEmice. Consistent
with these ﬁndings was the reduction of Treg cell numbers at the peak of disease, as well as a signiﬁcant decline in the expression levels
of Foxp3, IL-10 and TGF-β in the CNS. Upon treatment with globular adiponectin, ADPKO-EAE mice showed rapid symptomatic improve-
ment, and their Treg cell number was restored to normal [130].
Overall, it can be appreciated that an inversely proportional relationship operates between obesity and adiponectin secretion and cir-
culating levels. What is more, increased obesity leads to decreased adiponectin secretion and circulation, which in turn raises the risk of
MS (i.e. CNS inﬂammation, demyelination and axon injury). Increased obesity correlates with less deposition of adiponectin, and thus a
shift of favourable anti-inﬂammatory/pro-resolving responses to unfavourable pro-inﬂammatory responses.
Moving on, the second theory proposes that the underlying cause is vitamin D deﬁciency in obese individuals. In a study conducted
on 217 obese children (118 female and 99 male), more than half suffered from vitamin D deﬁciency (<20 ng/ml) [133]. In a separate study
done on 68 obese adolescents, vitamin D levels were signiﬁcantly low in 100% of female subjects and 91% of male subjects. However,
after the treatment course with vitamin D, only 28% of the subjects showed enhancement in vitamin D levels; the remaining 72% failed
to show an increase in their vitamin D levels [134]. Furthermore, an investigation performed on 6275 subjects from the National Health
and Nutrition Examination Survey (2001–2004) concluded that obese subjects are more likely to have vitamin D deﬁciency (OR = 1.9) [135].
Thus, it is evident that obese individuals are at a greater risk of developing MS in part due to vitamin D deﬁciency.
Lastly, the third theory highlights a role for inherent genetic makeup. Obesity was found to be highly associated with certain geno-
types predisposing to MS (carriage of HLA-DRB1*15 and absence of HLA-A*02) with OR = 16.2 (95% C.I. =7.5–35.2) [136–138]. If anything,
this report suggests that rather than being a direct risk factor, obesity can be genetically inherited in such a way so as to increase the risk
of developing MS.
7.1.5.2. Obesity in Arabian Gulf countries. In a recent study, Kuwaiti adolescents showed the highest prevalence of overweight and obesity
amongst ﬁve Arab countries (reaching 40% for male and 37.3% for female in the age of 15 years) [139]. Whereas, in Dubai, U.A.E., the per-
centage of obesity reached 27.2% amongst male and 20.5% amongst female students between the ages of 12 and 17 years [140].
Additionally, in Al-Hassa, K.S.A., in King Faisal University, 64% of the employees were either overweight or obese [141]. Whilst in Dammam
and Qatif areas, eastern provinces of K.S.A., 60.3% of mothers were found to be either overweight or obese [142]. Even more, according to
the Oman World Health Survey (OWHS), 24.1% of the population in the age of 18 or above are considered obese [143]. All of those data
could explain the increased incidence and prevalence of MS in Arabian Gulf countries.
Even more, Qatar and Kuwait were found to be among few other countries with estimated adults’ prevalence of obesity exceeding
50% for women, a fact that could explain increased incidence of MS in women [144].
7.1.6. Alcohol
Alcohol constitutes another possible MS predisposing factor. In 1999, a survey conducted on 168 MS patients in Northern California
pinpointed an association between alcohol consumption and lower EDSS scores and less total disability [145]. In another study, regular
consumption of alcohol and wine was found to decrease the risk of attaining an EDSS score of 6 in a group of 1372 persons with deﬁnite
MS in Belgium [112]. Moreover, results from a group of 2469 conﬁrmed MS cases veriﬁed that moderate alcohol consumption is associ-
ated with increased HRQOL and lower numbers of signiﬁcant disability (41% decrease) [115]. In a separate case-control study of 423 subjects,
272 of which were MS patients, a further protective role for alcohol consumption was proven. In particular, this was true for lowering
EDSS scores and amelioration of lateral ventricle lesions (NLVV). On the contrary, however, alcohol consumption correlated with a risk of
developing higher numbers of grey matter lesions (NGMV) [146]. Other reports suggest a dose-dependent relationship between alcohol
consumption and protection from MS [136–138]. Paradoxically, though, Pekmezovic and colleagues found that consumption of hard-
liquors per day is associated with a risk of developing MS [94].
Furthermore, data gathered from a study on 258 MS female cases from the Nurses’ Health study I and II have shown no signiﬁcance
for alcohol, beer, wine, or liquor consumption on MS risk [147]. A similar conclusion was established in another study conducted on 282
MS cases and 558 controls [106]. All in all, alcohol may be a probable protective factor in MS development, but this conjecture still re-
quires extensive veriﬁcation. Alcohol consumption effect on MS disease can not be estimated in AGC. Citizens of those countries are by
majority Muslims, whose religion forbid alcohol consumption. As a results, alcohol consumption would not be an effective factor in the
study of MS.
7.2. MS genetic susceptibility factors
In this review, only the Caucasian genetic susceptibility factors will be discussed as this review tries to get a glance of MS in the Arabian
Gulf countries only.
7.2.1. HLA loci
Most linkage results with MS were reported on HLA-DRB1*15:01 (1.83 × 10−17), accounting for less than 50% of the genetic basis of the
disease. However, other HLA regions have also been strongly linked toMS, including HLA-A (P = 7 × 10−12),HLA-DR2/HLA-DQB1*0602 (P < 0.001),
TNF (P = 0.018) and HLA-C*05 (P = 0.04) [148–151]. The family of HLA genes accounts for antigen receptor proteins that function in regu-
lating the immune system [152]. As MS is considered to develop from the disruption of two systems (immune and nervous), immunity-
related genes would be expected to be associated. This is especially true of HLA genes, as they play major roles in immune regulation.
27E.M.A. Mohammed / Pathogenesis 3 (2016) 19–38
7.2.2. Non-HLA loci
Apart from HLA loci, GWAS and linkage studies have also investigated several non-HLA loci, which function in the immune system,
nervous system, haemostatic system, or genes with unknown functions. Tables 1 to 8 illustrate the genes with known association to MS
in Caucasians either by GWAS or by linkage studies ordered according to their function and chromosomal locations.
On Table 2 an interesting possible association was found recently between MS and NOS3 gene in Kuwaiti population [174]. This gene
encodes for endothelial nitric oxide synthase protein that functions in increasing cGMP in smooth muscle, acts as a vasodilator, and modu-
lates BBB permeability and cerebral blood ﬂow (CBF). However, further investigation with larger number of samples must be done to prove
such association in the Kuwaiti population and maybe in the Arabian Gulf countries.
7.3. Epigenetic factor
Several epigenetic factors have been suggested to affect MS development, including DNAmethylation, histone deacetylation, and mRNA
methylation. A glance revision of those epigenetic factors could illustrate some unresolved dilemma.
7.3.1. DNA methylation effect on MS
DNA methylation entails the covalent addition of methyl groups to cytosine nucleotides on DNA strands. In MS patients, DNA
hypomethylation was reported in the Peptidylarginine deiminase 2 (PAD2) gene. PAD2 encodes an enzyme involved in the citrullination
of MBP. Hypomethylation of PAD2 leads to increased MBP citrullination. This modiﬁcation promotes MBP autocleavage, and thereby pro-
duces novel epitopes for MBP auto-reactivity. In mice, increased expression and activity of PAD2 correlates with exacerbated clinical signs
of severe focal demyelination and myelin thinning [175]. Hence, DNA methylation may contribute to MS development through affecting
the status of cortical myelin.
7.3.2. Histone modiﬁcation effect on MS
Histone modiﬁcation is a process whereby various molecules are post-translationally and covalently added to the histone subunits of
nucleosomes. Oligodendrocyte differentiation and remyelination processes have been reported to be affected by histone deacetylation at
promoter regions of the genes involved. Older MS patients seem to display impaired histone deacetylation, and thereby fail to undergo
eﬃcient remyelination. Moreover, MBP citrullination can induce irreversible effects on histone structure, in that arginine demethylation
halts gene activation [175]. To wit, PAD2 hypomethylation can thus not only induce MBP auto-reactivity, but also irreversible gene inac-
tivation and, consequently, MS development.
Table 1
Global distribution of Immune genes shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
CD58 European 1p13 rs12044852 9.71 × 10−4 1.48 Cell–cell adhesion IMSGC et al. [153]
rs1335532 2.00 × 10−09 1.18 IMSGC et al. [154]
FCRL1 European 1q21-q22 rs2050568 1.33 × 10−06 1.08 Function in regulation of cancer cell growth. IMSGC et al. [155]
KIF21B European 1q32.1 rs7522462 9.20 × 10−07 1.11 Encodes a member of the kinesin superfamily.
Kinesins are ATP-dependent microtubule-based
motor proteins that are involved in the
intracellular transport of membranous organelles.
IMSGC et al. [154]
VCAM1 European 1p32-p31 rs11581062 2.50 × 10−10 1.07 Encodes member of the Ig superfamily, a cell
surface sialoglycoprotein expressed by cytokine-
activated endothelium. This type I membrane
protein mediates leucocyte-endothelial cell
adhesion and signal transduction.
IMSGC et al. [154]
rs12048904 4.00 × 10−08 1.08
PLEKHG5 European 1p36.31 rs3007421 9.6 × 10−7 1.12 Encodes a protein that activates the nuclear factor
kappa B (NFKB1) signalling pathway.
IMSGC et al. [155]
MERTK European
ancestry
2q14.1 rs867311 5.41 × 10−5 0.86 It has a role in phagocytosis of apoptotic cells,
regulation of dendritic cell activation, T cell
selection and tolerance, and B cell homeostasis
and tolerance.
Ma et al. [156]
rs12477716 5.50 × 10−5 0.86
rs17835605 5.96 × 10−5 0.85
rs4278932 6.96 × 10−5 0.86
rs4528767 5.91 × 10−5 0.87
rs17174870 7.76 × 10−5 0.86
rs1516629 8.24 × 10−5 0.85
rs1400325 2.25 × 10−4 0.86
rs4434006 1.79 × 10−4 0.86
rs11884641 1.79 × 10−4 0.68
rs7568632 1.89 × 10−4 0.86
rs12469210 4.06 × 10−4 0.87
rs1516640 4.45 × 10−4 1.01
rs4848901 7.91 × 10−4 1.02
rs13419523 1.27 × 10−3 1.13
rs6730521 1.83 × 10−3 1
rs3811632 0.03 1.02
IL-1RA/IL-1beta Dutch 2q14.2 IL-1RA allele
2+/IL-1beta
allele 2−
0.007 – IL-1RA: inhibits the activities of interleukin 1,
alpha (IL1A) and interleukin 1, beta (IL1B), and
modulates a variety of interleukin 1-related
immune and inﬂammatory responses.
Schrijver et al. [157]
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7.3.3. mRNA methylation effect on MS
DNA methylation and histone modiﬁcation can exert dual effects on microRNAs (miRNAs) and small interfering RNAs (siRNAs). The
former are small, non-coding RNA molecules of 22–23 bp that post-transcriptionally regulate many genes involved in apoptosis, the cell
cycle, and immune pathways. Speciﬁcally, miRNAs modulate genome expression via a silencing mechanism, and they in turn are subject
to modulation through epigenetic mechanisms (e.g. methylation of tandem repeats). miRNAs are either downregulated or upregulated in
different MS clinical phases. An exemplary miRNA is miR-326, the expression of which was found to be signiﬁcantly higher during the
relapsing phase. That of hsa-miR-18b, hsa-miR-599, and hsa-miR-96, on the contrary, was signiﬁcantly higher in the remission phase [175,176].
Further, hsa-miR-20a-5p and hsa-miR-20b-5p, which play central roles in gene regulation and T-cell activation, were found to be asso-
ciated with MS development [177,178].
7.3.4. Effect of epigenetic markers and environmental factors on MS
Environmental factors, such as smoking, vitamin D levels, and EBV infection, were suggested to affect or be affected by epigenetic markers,
thereby explaining the role of environmental factors on the development of the MS.
Epigenetic factors affect vitamin D levels through modulating two genes: the 1α-hydroxylase gene, and the vitamin D 24-hydroxylase
gene. The former encodes a protein that catalyses the formation of active vitamin D hormone; the latter encodes a protein that degrades
the active form of vitamin D [175,178]. As such, vitamin D levels inMS patients could be disrupted as a result of faulty epigenetic interventions.
Whereas vitamin D is affected by epigenetic factors, the EBV latent membrane protein 1 (LMP1) affects the expression and activity of
the DNA methyltransferases 1, 3A, and 3B. This in turn results in disruption of the epigenetic status of a number of host genes, and may
therefore induce MS [175,178].
Smoking has also been linked to signiﬁcantly increased DNA hypermethylation patterns in the promoters of several cancer-related genes
in non-small cell lung cancer patients when compared with patients who had never smoked. Thus, epigenetic modiﬁcations may play a
role in smoking’s contribution to MS development [175,178].
Moreover, inheritance of such epigenetic factors is suggested to explain the inheritance pattern of MS through generations. Experimen-
tal studies on mice have shown that environmental epigenetic changes can persist through generations [175]. However, in a study with MS
monozygotic twins, no such proof for epigenetic or transcriptome differences that explained disease development was found [179].
Table 2
Global distribution of immune genes shown to be associated with MS.
Gene Ethnicity Susceptibility loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
CXCR4 Caucasian 2q21 rs882300 – 1.19 Acts with the CD4 protein to support HIV entry into
cells and is also highly expressed in breast cancer cells
De Jäger et al. [158]
CBLB Sardinian 3q13.11 rs9657904 1.60 × 10−10 1.4 Negative regulator of adaptive immune responses Sanna et al. [172]
European rs2028597 2.10 × 10−04 1.13 IMSGC et al. [154]
CD86 European 3q21 rs9282641 1.00 × 10−11 1.2 Antigen receptor IMSGC et al. [154]
rs4285028 1.80 × 10−08 1.09
rs4308217 5.70 × 10−08 1.09
rs1920296 6.8 × 10−15 – IMSGC et al. [155]
IL12A Caucasian 3q25.33-q26 rs4680534 – 1.12 Acts on T and natural killer cells, and has a broad array
of biological activities
De Jäger et al. [158]
European rs2243123 3.70 × 10−06 1.09 IMSGC et al.
011 [154]
IL7RA European 5p13 rs6897932 2.94 × 10−7 1.18 Transmembrane domain of the IL7Rα chain of the
interleukin-7 receptor
IMSGC et al. [153]
2.60 × 10−06 1.11 IMSGC et al. [154]
PTGER4 Caucasian 5p13.1 rs6896969 – 1.1 This receptor can activate T-cell factor signalling. De Jäger et al. [158]
European rs4613763 6.90 × 10−14 1.21 IMSGC et al. [154]
IL12B European 5q31.1-q33.1 rs2546890 1.20 × 10−11 1.15 Cytokine that acts on T and natural killer cells, and has
a broad array of biological activities.
IMSGC et al. [154]
HLA Caucasian
Irish
6p21 D6S1615 0.0047 – Antigen receptor Heggarty et al. [173]
TNFa 0.0055 –
D6S1014 0.0366 –
HLA-DRB1*15:01 European 6p21.3 rs9270986 1.83 × 10−17 5.8 Antigen receptor IMSGC et al. [153]
rs9271366 7.8 × 10−169 3.19 Field et al. [152]
HLA-A Caucasian 6p21.3 A*02 7 × 10−12 0.63 Antigen receptor Brynedal et al. [148]
HLA-C*05 British 6p21.3 Entire allele 0.04 ND Act as ligands for the killer cell immunoglobulin like
receptors (KIRs)
Yeo et al. [151]
HLA-DRB1*03:01 European 6p21.3 rs2187668 3:1 × 10−24 2.01 Antigen receptor Field et al. [152]
HLA-DPB1 European 6p21.3 rs9277535 2.3 × 10−10 1.27 Antigen receptor Field et al. [152]
HLA-DR2/HLA-DQB1*0602 American 6q21 HLA-DR <0.001 4.6 Antigen receptor Haines et al. [149]
OLIG3/TNFAIP3 Caucasian 6q23 rs9321619 – 1.12 Inhibit NF-kappa B activation as well as TNF-mediated
apoptosis
De Jäger et al. [158]
European rs13192841 2.30 × 10−06 1.10 IMSGC et al. [154]
rs7769192 1.30 × 10−05 1.08 IMSGC et al. [155]
IL22RA2 European 6q23.3 rs17066096 6.00 × 10−13 1.14 Inhibits interleukin 22 activity. IMSGC et al. [154]
ELMO1 European 7p14.1 rs60600003 2.53 × 10−08 1.16 Promote phagocytosis and cell migration IMSGC et al. [155]
NOS3 Kuwaiti 7q36.1 eNOS-27VNTR 0.02 0.89 Increasing cGMP in smooth muscle, act as a
vasodilator and modulate BBB permeability and CBF.
Alfadhli et al. [174]
IL7 European 8q12-q13 rs1520333 6.10 × 10−07 1.11 Encode cytokine important for B and T cell development. IMSGC et al. [154]
IL2RA European 10q15 rs2104286 2.16 × 10−7 1.19 Alpha chain of the interleukin-2 receptor IMSGC et al. [153]
rs12722489 2.96 × 10−8 1.25
rs3118470 2.00 × 10−09 1.12 IMSGC et al. [154]
rs7090512 4.60 × 10−20 1.21
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7.4. Mitochondrial genome
Production of ROS is one of the important roles of the mitochondrial oxidation process. Disruption of this mechanism could cause mi-
tochondrial damage through over production of ROS. This could further cause neurodegeneration seen in MS patients’ cortex. Several studies
have associated the mitochondrial oxidation-related genes with susceptibility to MS [180,181].
Moreover, evidence of disrupted mitochondrial respiratory chain activity and downregulation of mitochondrial DNA in MS have also
been mentioned in a couple of papers [180,181]. Examples of mitochondrial genes that are either upregulated or downregulated in cortex
tissues of different MS stages have been reviewed previously [182–186].
Furthermore, a decline in the copy numbers of mitochondrial DNA in late-onset MS has been reported, suggesting yet another role for
mitochondrial genes in MS development [187].
Table 3
Global distribution of immune genes shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
CD6 Caucasian 11q13 rs17824933 3.79 × 10−9 1.18 Molecule involved in T-cell costimulation and
differentiation
De Jäger et al. [158]
European rs650258 1.70 × 10−09 1.12 IMSGC et al. [154]
CXCR5 European 11q23.3 rs630923 2.80 × 10−07 1.13 Involve B-cell migration into B-cell follicles of
spleen and Peyer patches.
IMSGC et al. [154]
TNFRSF1A Caucasian 12p13.2 rs1800693 1.59 × 10−11 1.2 Primarily immunologic functions De Jäger et al. [158]
European 1.80 × 10−10 1.12 IMSGC et al. [154]
CLECL1 European 12q13.31 rs10466829 1.40 × 10−08 1.12 Act as a T-cell costimulatory molecule that
enhances interleukin-4 production.
IMSGC et al. [154]
CYP27B1 European 12q14.1 rs12368653 2.00 × 10−07 1.11 Hydroxylates 25-hydroxyvitamin D3 at the 1alpha
position
IMSGC et al. [154]
INF-γ Sardinian 12q24 – 0.004 – Soluble cytokine with antiviral, immunoregulatory
and anti-tumour properties and is a potent
activator of macrophages
Vandenbroeck
et al. [159]
TRAF3 European 14q32.32 rs12148050 1.47 × 10−05 1.08 Signal transduction from members of the TNF
receptor (TNFR) superfamily
IMSGC et al. [155]
GPC5 Spanish 13q31.3 rs9523762 1.6 × 10−5 1.23 Glypicans 5 regulate cell–cell signalling Cavanillas et al. [31]
CLEC16A European 16p13.13 rs7200786 6.30 × 10−14 1.15 This gene encodes a member of the C-type lectin
domain containing family.
IMSGC et al. [154]
IRF8 – 16q24.1 rs17445836 3.73 × 10−9 – Encodes a transcription factor known to function
in type I interferon signalling
De Jäger et al. [158]
European rs13333054 7.00 × 10−08 1.12 IMSGC et al. [154]
NOS2A Italian 17q11.2-12 (CCTTT)n 0.03 – Produce NO during the inﬂammation process as
host defence molecule
Manna et al. [160]
Spanish 0.02 – Blanco et al. 003 [161]
CD226 British and
American
18q22 rs763361
accounting
for Gly307Ser
4.20 × 10−4 1.1 Involved in the adhesion and co-stimulation of T
cells
Haﬂer et al. [162]
TYK2 Caucasian 19p13.2 rs34536443 2.7 × 10−06 1.32 Signal transduction for a wide range of cytokines,
including type 1 interferons, IL10 and IL12
Ban et al. [163]
European rs8112449 1.50 × 10−06 1.10 IMSGC et al. [154]
ICAM1 Polish 19p13.2-13.3 E469 0.001 – Plays an important role in the cascade of adhesion
events in the homing of inﬂammatory cells to the
central nervous system
Mycko et al. [164]
K469 0.02 –
TNFSF14 European 19p13.3 rs1077667 9.40 × 10−14 1.14 Costimulatory factor for the activation of lymphoid
cells and as a deterrent to infection by herpesvirus.
IMSGC et al. [154]
Upstream of
CD40/TNFRSF5
Australian 20q13 rs6074022 1.3 × 10−7 – Costimulatory molecule on B cells, dendritic cells,
macrophages and microglia.
ANZgene [165]
CD40 European 20q13 rs2425752 1.70 × 10−06 Costimulatory molecule on B cells, dendritic cells,
macrophages and microglia.
IMSGC et al. [154]
TNFRSF5 European 20q13 rs1569723 2.9 × 10−7 – Costimulatory molecule on B cells, dendritic cells,
macrophages and microglia.
IMSGC et al. [154]
Table 4
Global distribution of Neuronal system genes shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
ALK European 2p23 rs7577363 1.14 × 10−4 2.1 Brain development IMSGC et al. [153]
IFIH1-KCNH7 Spanish 2q24.3 rs2068330 0.001 0.7 IFIH1: gene encodes a cytoplasm viral detector
critical for response to picornaviruses. KCNH7:
Voltage-dependent K + channels are the main
determinants in controlling cellular
excitability within the central nervous system.
Martínez et al. [26]
ANKRD15 European 9p24 rs10975200 8.05 × 10−3 1.3 Speciﬁc function is unknown, neuronal
development
IMSGC et al. [153]
ACCN1 Italian (speciﬁcally
Nuoro population)
17q11.2 rs28936 0.002 2.1 Generate ionic currents involved in the
transmission of the nervous signal
Bernardinelli
et al. [166]
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A recent meta-analysis study has rolled out the risk of almost 41 factors and proved the risk of only EBV virus, infectious mononucle-
osis and smoking on MS (p = 1.5 × 10−19, 3.1 × 10−50, 1.7 × 10−18, respectively). The data were collected from the time of PubMed establishment
to November 2014, including 44 risk factors and 416 published papers [188]. This may throw away all studies made so far and point
only to three factors, but one must not exclude that such meta-analysis studies include combined data from different ethnicity,
population and continents in one statistical approach. This bias only could compromise the meta-analysis results, as MS prevalence has
been found to be effected by ethnicity, regional latitude and even community customs and traditions [8]. MS is a heterogeneous complex
disease that shows different prevalence and risk factors between different populations; even more symptoms, severity and disease
development differs between individuals in the same ethnicity, population or regional latitude. Not to forget that such studies relay on
reproductive researches. Knowing that some factors have not been well studied would explain why they would be rolled out. In
conclusion, the meta-analysis could point to the importance of EBV virus, infectious mononucleosis and smoking as risk factors for MS;
however, further studies must be conducted to deﬁne the risk of the remaining factors on MS on the basis of ethnicity, population and
regional latitude.
8. MS diagnosis
So what criteria are taken to diagnose a patient with MS? Several criteria have been made to ease the diagnosis of MS: Schumacher
criteria, Poser criteria, Barkhof–Tintoré criteria and McDonald criteria. The information giving by the ﬁrst criterion was further evaluated
in the next criterion and supported with more diagnostic tools. The ﬁrst internationally recognised criterion was the Schumacher crite-
rion that introduced the concept of clinically deﬁnite MS (CDMS). Following that, Poser has introduced more concepts in his criterion to
the MS diagnosis. Subsequently, Barkhof and Tintoré introduced the MRI in the diagnosis of MS which was further assayed by McDonald
in his criterion [189].
The latest diagnostic criteria for MS are the revised McDonald criteria set in 2010 [190]. These criteria are currently used for the MS
diagnosis in Arabian Gulf countries [15]. The criteria entail clinical and paraclinical laboratory assessments highlighting the need to dem-
onstrate dissemination of lesion in space (DIS) and time (DIT), and to exclude alternative diagnosis. According to these criteria, a patient
diagnosed with MS must fulﬁl one of the criteria indicated in Table 9.
In case of a suspect with incompletely met criteria, the patient must be diagnosed as having “possible MS”. Notwithstanding, if another
diagnosis that better explains the clinical presentation arises during the evaluation, the patient’s diagnosis must be “not MS”, as in fact
MS is diagnosed when there is no better explanation for patients’ symptoms after excluding all other possible diagnoses.
Table 5
Global distribution of haemostasis genes shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
PHGDH European 1p12 rs666930 7.49 × 10−08 1.09 Involved in the early steps of l-serine synthesis in
animal cells
IMSGC et al. [155]
DDAH1 European 1p22 rs11587876 8.4 × 10−08 1.12 Nitric oxide generation IMSGC et al. [155]
EVI5 European 1p22 rs10735781 2.21 × 10−4 1.29 Cell cycle control IMSGC et al. [153]
rs11810217 6.50 × 10−12 1.15 IMSGC et al. [154]
FAM69A European 1p22 rs7536563 2.53 × 10−5 1.34 Protein binding IMSGC et al. [153]
rs11164838 6.01 × 10−5 1.32
RPL5 European 1p22 rs6604026 4.45 × 10−4 1.29 Ribosomal protein, chaperone for the 5S rRNA IMSGC et al. [153]
RGS1 Caucasian 1q31 rs2760524 – 1.15 Encodes a member of the regulator of G-protein
signalling family
De Jäger et al. [158]
European rs1323292 8.80 × 10−07 1.12 IMSGC et al. [154]
MMEL1 Caucasian 1p36 rs3748816 3.54 × 10−5 1.16 Pain perception, arterial pressure regulation,
phosphate metabolism and homeostasis.
Ban et al. [167]
European rs4648356 3.10 × 10−14 1.16 IMSGC et al. [154]
KIF1B Caucasian 1p36.22 rs10492972 2.5 × 10−10 1.35 Axonal transport of mitochondria and synaptic vesicle
precursors
Aulchenko et al. [168]
CENPO European 2p23.3 rs4665719 6.80 × 10−06 1.09 Bipolar spindle assembly, chromosome segregation
and checkpoint signalling during mitosis.
IMSGC et al. [155]
STAT4 European 2q32.2-q32.3 rs9967792 1.80 × 10−09 1.11 Mediate responses to IL12 in lymphocytes, and
regulating the differentiation of T helper cells.
IMSGC et al. [155]
FOXP1 European 3p14.1 rs9828629 5.49 × 10−06 1.08 Regulate tissue- and cell type-speciﬁc gene
transcription during both development and adulthood.
IMSGC et al. [155]
EOMES European 3q24.1 rs11129295 1.20 × 10−09 1.09 Transcription factor IMSGC et al. [154]
NFKB1 European 4q24 rs228614 1.40 × 10−07 1.09 Transcription regulator IMSGC et al. [154]
TET2 European 4q24 rs2726518 1.23 × 10−05 1.09 Involve in myelopoiesis. IMSGC et al. [155]
RGS14 European 5q35.3 rs4976646 1.04 × 10−12 1.13 Regulator of G-protein signalling IMSGC et al. [155]
TNF Spanish 6p21.3 TNF-376A 0.018 1.87 Regulator of cell proliferation, differentiation,
apoptosis, lipid metabolism, and coagulation.
Martínez et al. [150]
NOTCH4 European 6p21.3 rs2854050 4.3 × 10−12 0.6 Controlling cell fate decisions Field et al. [152]
rs3830041 6.3 × 10−8 1.41
THEMIS European 6q22.33 rs802734 5.50 × 10−09 1.13 Regulator of positive and negative T-cell selection
during late thymocyte development.
IMSGC et al. [154]
MYB European 6q22-q23 rs11154801 1.00 × 10−13 1.09 Regulator of haematopoiesis and may play a role in
tumourigenesis.
IMSGC et al. [154]
TAGAP European 6q25.3 rs1738074 6.80 × 10−15 1.14 Rho GTPase-activating protein IMSGC et al. [154]
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Table 6
Global distribution of haemostasis genes shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product Function Ref.
Chromosomal
location
SNP P-value OR
JAZF1 European 7p15.2-p15.1 rs917116 2.07 × 10−08 1.12 Transcriptional repressor IMSGC et al. [155]
MYC European 8q24.21 rs4410871 7.70 × 10−09 1.09 Involved in cell cycle progression, apoptosis and cellular
transformation
IMSGC et al. [154]
DBC1 European 9q33 rs10984447 1.18 × 10−4 1.36 Cell cycle arrest, apoptosis IMSGC et al. [153]
ZMIZ1 Caucasian 10q22.3 rs1250540 – 1.12 Regulates the activity of various transcription factors,
including the androgen receptor, Smad3/4, and p53
De Jäger et al. [158]
European rs1250550 1.40 × 10−06 1.10 IMSGC et al. [154]
VDR Italian 12q13.11 rs731236 0.004 0.53 This gene encodes the nuclear hormone receptor for
vitamin D3.
Agliardi et al. [45]
HHEX European 10q23.33 rs7923837 4.90 × 10−09 1.09 Transcription factor IMSGC et al. [154]
DHCR7 Spanish 11q13.4 rs12785878 0.009 1.10 Removes the C(7–8) double bond in the B ring of sterols Alloza et al. [169]
ZFP36L1 European 14q22-q24 rs4902647 9.30 × 10−12 1.13 Transcription factor that act in regulating the response to
growth factors.
IMSGC et al. [154]
BATF European 14q24.3 rs2300603 2.00 × 10−08 1.08 Negatively regulator of AP-1/ATF transcriptional events. IMSGC et al. [154]
GALC European 14q31 rs2119704 2.20 × 10−10 1.12 Hydrolyses galactose ester bonds IMSGC et al. [154]
IQGAP1 European 15q26.1 rs8042861 9.80 × 10−07 1.08 Regulate cell morphology and motility IMSGC et al. [155]
SOX8 European 16p13.3 rs2744148 8.40 × 10−08 1.12 Involve regulation of embryonic development and in the
determination of the cell fate.
IMSGC et al. [154]
CDH3 European 16q22.1 rs1886700 8.76 × 10−06 1.11 Involved in loss of heterozygosity events in breast and
prostate cancer.
IMSGC et al. [155]
WWOX European 16q23.3-q24.1 rs12149527 1.74 × 10−06 1.08 Regulate a wide variety of cellular functions such as protein
degradation, transcription, and RNA splicing.
IMSGC et al. [155]
STAT3 Finnish 17q21.1 rs744166 1.6 3 × 10−25 0.87 Transcription factor Jakkula et al. [170]
European rs9891119 4.60 × 10−07 1.10 IMSGC et al. [154]
RPS6KB1 European 17q23.1 rs180515 8.80 × 10−08 1.05 Promote protein synthesis, cell growth, and cell proliferation. IMSGC et al. [154]
MALT1 European 18q21 rs7238078 2.50 × 10−09 1.14 NF-kappa B activation IMSGC et al. [154]
DKKL1 European 19q13.33 rs2303759 5.20 × 10−09 1.11 Interacts with theWnt signalling pathway. IMSGC et al. [154]
CYP24A1 European 20q13 rs2248359 2.50 × 10−11 1.11 Catalyse many reactions involved in drug metabolism and
synthesis of cholesterol, steroids and other lipids.
IMSGC et al. [154]
SLC9A8 European 20q13.13 rs17785991 6.42 × 10−07 1.09 Integral transmembrane proteins that exchange extracellular
Na+ for intracellular H+.
IMSGC et al. [155]
TNFRSF6B European 20q13.3 rs6062314 1.30 × 10−07 1.14 The encoded protein is postulated to play a regulatory role in
suppressing FasL- and LIGHT-mediated cell death.
IMSGC et al. [154]
SLC2A4RG European 20q13.33 rs2256814 8.34 × 10−07 1.11 Nuclear transcription factor involved in the activation of the
solute carrier family 2 member 4 gene.
IMSGC et al. [155]
MAPK1 European 22q11.21 rs2283792 4.70 × 10−09 1.12 Acts as an integration point for multiple biochemical signals. IMSGC et al. [154]
SCO2 European 22q13.33 rs140522 1.70 × 10−08 1.12 Catalyses the transfer of electrons from cytochrome c to
molecular oxygen.
IMSGC et al. [154]
Table 7
Global distribution of genes with unknown function shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product
Function
Ref.
Chromosomal
location
SNP P-value OR
BCL10(dist = 4406), DDAH1 (dist = 37175) European 1p22 rs12087340 5.13 × 10−12 1.22 – IMSGC et al. [155]
SLAMF7 European 1q23.1-q24.1 rs35967351 1.70 × 10−06 1.09 – IMSGC et al. [155]
No gene European 2 rs12466022 6.20 × 10−10 1.16 – IMSGC et al. [154]
PLEK European 2p13.3 rs7595037 5.10 × 10−11 1.15 – IMSGC et al. [154]
FLJ16341 European 2p16.1 rs842639 1.70 × 10−09 1.11 – IMSGC et al. [155]
SP140 European 2q37.1 rs10201872 1.80 × 10−10 1.15 – IMSGC et al. [154]
No gene European 3 rs669607 1.90 × 10−15 1.15 – IMSGC et al. [154]
SATB1 (dist = 305320), KCNH8 (dist = 404432) European 3p23 rs11719975 5.39 × 10−06 1.09 – IMSGC et al. [155]
CCR4 (dist = 17080), GLB1 (dist = 24617) European 3p24 rs4679081 1.20 × 10−05 1.08 – IMSGC et al. [155]
TMEM39A European 3q13.33 rs2293370 1.10 × 10−09 1.16 – IMSGC et al. [154]
ANKRD55 Spanish 5q11.2 rs6859219 2.3 × 10−9 1.35 – Alloza et al. [169]
VDAC1 (dist = 105751), TCF7 (dist = 3827) European 5q31 rs756699 2.97 × 10−06 1.12 – IMSGC et al. [155]
PXT1 European 6p21.31 rs941816 4.47 × 10−09 1.13 – IMSGC et al. [155]
C6orf10 European 6p21.32 rs3129939 2.0 × 10−13 0.62 – Field et al. [152]
Spanish-US rs3129934 1.4 × 10−05 3.0 Comabella et al. [171]
LOC285830 European 6p22.1 rs2394160 8.1 × 10−17 0.79 – Field et al. [152]
CD83 (dist = 582348), JARID2 (dist = 526710) European 6p23 rs17119 1.91 × 10−06 1.11 – IMSGC et al. [155]
BACH2 European 6q15 rs12212193 3.80 × 10−08 1.08 – IMSGC et al. [154]
C7orf72 (dist = 126715), IKZF1 (dist = 18811) European 7p12.2 rs201847125 2.91 × 10−08 1.11 – IMSGC et al. [155]
SKAP2 (dist = 110647), HOXA1 (dist = 117626) European 7p15.2 rs706015 1.29 × 10−09 1.14 – IMSGC et al. [155]
CARD11 (dist = 29525), SDK1 (dist = 228046) European 7p22 rs1843938 2.21 × 10−06 1.08 – IMSGC et al. [155]
ZNF767 European 7q36.1 rs354033 4.70 × 10−09 1.14 – IMSGC et al. [154]
PVT1 European 8q24 rs2019960 5.20 × 10−09 1.16 – IMSGC et al. [154]
PCAT1 European 8q24.21 rs2456449 2.21 × 10−08 1.10 – IMSGC et al. [155]
ZNF438(dist = 94240), ZEB1-AS1 (dist = 190351) European 10p11.23 rs793108 5.61 × 10−08 1.09 – IMSGC et al. [155]
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8.1. IgG oligoclonal bands (OCBs)
Evidence of intrathecal IgG synthesis in MS patients as a response to immune activation in the CNS has made the IgG index as one of
the diagnostic criteria in the past. Although not only MS patients show intrathecal IgG synthesis, this indicator adds to the diagnosis of
the patients [80,81]. The sensitivity of this tool has made it a good diagnostic tool. However, the revised McDonald criteria have with-
drawn CSF OCB test, except for PPMS which still use CSF OCB for diagnosis, and replaced it with the MRI, which has a better sensitivity
and speciﬁcity. Currently, CSF OCBs are only done in those who do not satisfy the revised criteria from the ﬁrst presentation and needed
DIS evidence, or in those who have red ﬂags in clinical presentation or imaging.
8.2. Evoked potentials tests (EP)
Paraclinical tests, such as the Evoked Potentials test, are usually used to assess the likelihood of having MS. The evoked potential or
evoked response test is a record that establishes the electrical potential of the nervous system after its stimulation by an external stimulus.
Theywere ﬁrst assisted byDawson in 1947. The responses are assayed throughmeasuring the peak amplitudes and latencies in themillisecond
Table 8
Global distribution of genes with unknown function shown to be associated with MS.
Gene Ethnicity Susceptibility Loci Gene Product
Function
Ref.
Chromosomal
location
SNP P-value OR
CAMK2G (dist = 24000), C10orf55 (dist = 11378) European 10q22 rs2688608 6.37 × 10−05 1.07 – IMSGC et al. [155]
AGBL2 European 11p11.2 rs7120737 7.61 × 10−08 1.13 – IMSGC et al. [155]
PRDX5 (dist = 7938), CCDC88B (dist = 10457) European 11q13 rs694739 1.30 × 10−05 1.08 – IMSGC et al. [155]
TREH (dist = 16365), DDX6 (dist = 51727) European 11q23.3 rs533646 3.60 × 10−07 1.10 – IMSGC et al. [155]
DDX6 (dist = 62922), CXCR5 (dist = 29581) European 11q23.3 rs9736016 2.20 × 10−08 1.10 – IMSGC et al. [155]
LTBR (dist = 2768), CD27-AS1 (dist = 44667) European 12p13 rs12296430 3.62 × 10−10 1.14 – IMSGC et al. [155]
METTL1 Australian 12q13-14 rs703842 5.4 × 10−11 – – ANZgene [165]
AGAP2 Australian 12q13-16 rs12368653 1.0 × 10−7 – – ANZgene [165]
MPHOSPH9 Caucasian 12q24.31 rs1790100 – 1.11 – De Jäger et al. [158]
European rs949143 1.50 × 10−04 1.08 IMSGC et al. [154]
No gene Spanish-US 13q31.3 rs1327328 0.0018 1.9 – Comabella et al. [171]
MIR548AN (dist = 27705), TM9SF2 (dist = 67469) European 13q32.3 rs4772201 1.67 × 10−07 1.12 – IMSGC et al. [155]
MORF4L1 (dist = 17385), CTSH (dist = 6626) European 15q24 rs59772922 4.02 × 10−06 1.11 – IMSGC et al. [155]
KIAA0350 European 16p13 rs6498169 2.90 × 10−2 1.19 – IMSGC et al. [153]
CLEC16A (dist = 12760), SOCS1 (dist = 59468) European 16p13.13 rs4780346 6.80 × 10−06 1.09 – IMSGC et al. [155]
PRM1 (dist = 60798), RMI2 (dist = 3321) European 16p13.2 rs6498184 2.07 × 10−10 1.15 – IMSGC et al. [155]
MAPK3 (dist = 22333), CORO1A (dist = 37768) European 16p11.2 rs7204270 9.32 × 10−08 1.09 – IMSGC et al. [155]
MAF (dist = 14772), DYNLRB2 (dist = 925460) European 16q22-q23 rs7196953 2.65 × 10−05 1.08 – IMSGC et al. [155]
GRB7 (dist = 8839), IKZF3 (dist = 1591) European 17q12 rs12946510 8.51 × 10−06 1.08 – IMSGC et al. [155]
MRPL45P2 (dist = 27112), NPEPPS (dist = 11346) European 17q21.32 rs4794058 1.63 × 10−05 1.07 – IMSGC et al. [155]
SLC44A2 European 19p13.1 rs2288904 9.57 × 10−10 1.14 – IMSGC et al. [155]
EPS15L1 European 19p13.11 rs1870071 5.68 × 10−10 1.12 – IMSGC et al. [155]
MPV17L2 European 19p13.11 rs874628 1.30 × 10−08 1.07 – IMSGC et al. [154]
Table 9
McDonald diagnostic criteria.
Look for If not ? Note
– 2 attacks
– objective clinical evidence of one lesion
– evidence of DIS, established by ≥ 1 T2 lesions, in ≥2 of 4 MS-typical
regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal
cord).
– Wait for further
clinical attack
implicating a
different CNS site.
– Gadolinium-enhancing lesions are not necessary for the
diagnosis
– Patients with symptomatic lesions are barred from
consideration in subjects with brainstem or spinal cord
syndromes.
– 1 attack
– objective clinical evidence of ≥2 lesions
– evidence of DIT, illustrated by simultaneous presence of asymptomatic
gadolinium-enhancing and non-enhancing lesions at any time
– or a new T2 and/or gadolinium enhancing lesion(s) on follow-up MRI,
not mattering the time with reference to baseline scan
– Wait for a second
clinical attack to
illustrate the
diagnosis.
– 1 attack
– objective clinical evidence of 1 lesion
– evidence of DIS
– ≥ 1 T2 lesion in ≥ 2 of 4 MS-typical regions of the CNS
– evidence of DIT, which is by simultaneous presence of asymptomatic
gadolinium-enhancing and non-enhancing lesions at any time
– or appearance of new T2 and/or gadolinium enhancing lesion(s) on
follow-up MRI, not mattering the timing with reference to baseline scan.
– Wait for second
clinical attack
associated with a
different CNS site
– Called clinically isolated syndrome (CIS)
– Presence of DIS in the brain based on ≥ 1 T2 lesion in ≥ 2 of 4 MS-typical
regions
– Or presence of DIS in the spinal cord based on ≥ 2 T2 lesions in the cord.
– Or positive CSF evidence of oligoclonal bands and/or elevated IgG index.
– Evidence of ≥2 criteria in this section is needed to diagnose
PPMS in patients that show one year of disease progression.
– Gadolinium-enhancing lesions are not required and patients
with symptomatic lesions are excluded from consideration in
subjects with brainstem or spinal cord syndromes.
NOTE: According to the McDonald criteria, attack (relapse; exacerbation) is deﬁned as a patient-reported or an objectively observed event typical of acute inﬂammatory
demyelination events in the CNS, current or historical with duration of at least 24 hours, in the absence of fever or infection.
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(ms) domain, and the results are interrupted in numerical ﬁgures. The effectiveness of the tests in MS diagnosis relays on the ability of the
tests to detect abnormal sensory system conduction at time of undeﬁned neurological examination record, expose subclinical involvement
of a sensory system (silent lesion) when symptoms indicate lesions allocated to different CNS areas, identify the anatomic distribution and
the pathophysiology of a disease and, more importantly, supervise changes in a patient to different neurological status [191].
Approximately more than 50% of MS patients have abnormal Visual-evoked potentials (VEPs) with no history or clinical evidence of
optic nerve dysfunction. In contrast, some patients establish abnormality in Somatosensory-evoked potentials (SSEPs) and brain stem auditory-
evoked potentials (BAEPs) without detectable evidence of demyelination on MRI [192,193]. In 2010, Pelayo and his colleagues established
that a patient with all three evoked potentials being abnormal has an increased risk of developing moderate disability from MS indepen-
dently of MRI ﬁndings [194]. Currently, the evoked potentials are used only to diagnose PPMS.
Although MRI, CSF and EPs tests are available to diagnose MS patients, MS remains a clinical diagnosis and those tests are only sup-
portive measures to consolidate the diagnosis or exclude other diseases. As in fact, MS is diagnosed when there is no better explanation
for patients’ symptoms after excluding other possible diagnoses.
8.2.1. MS current therapy
Although no known cure is yet available for MS, several lines of treatment exist to improve patients’ quality of life and slow disease pro-
gression. Treatment approaches are divided as follows: management of acute MS exacerbations, symptomatic therapies, and disease-
modifying drugs. Therapy includes themanagement of acuteMS episodes through administration of corticosteroids, which inhibit the immune
system’s aggressive attacks and relieve symptoms. Afterward, therapy focuses on treating MS-related symptoms, such as fatigue, bowel and
bladder dysfunctionality, cogitative problems, pain, and depression. Patients who have suboptimal response or failure to respond to corti-
costeroids treatment are given one of the seven Food and Drug Administration (FDA)-approved drugs: IFNβ1a (Avonex, Rebif); IFNβ1b (Betaferon,
Extavia); glatiramer acetate (Copaxone); mitoxantrone (Novantrone); natalizumab (Tysabri); ﬁngolimod (Gilenya); and teriﬂunomide (Aubagio),
Lemtrada (campath-1H), dimethyl fumarate (BG-12), each with considerable beneﬁts and side effects. Most of those drugs are available in
AGC and used to control relapses and sluggish disease progression [15]. Moreover, some drugs are currently in clinical trials to assess their
safety and eﬃcacy in MS patients. These include laquinimod, and daclizumab (Zenapax). Most clinical trials are aiming to reach high scores
of NEDA (no evidence of disease activity) [15,195–198]. Drug usage differs in patients from case to case, availability and cost.
8.2.2. Perspectives
Literature reviews expand researchers’ view of the topic of interest, give them new ideas, and touch on the validity of old theories. In
this review, the author has established that MS is a neurological, autoimmune disease characterised by a wide range of symptoms that
manifests in patients mostly in their twenties and has attacked much more patients in Arabian Gulf countries through the last few years.
Clinically, MS is divided into four different subtypes: RRMS, PPMS, SPMS, and PRMS [2,4,5]. Patient disability status is typically measured
by the EDSS score [7]. Diagnosis of MS is carried out in accordance to the 2010 revised McDonald criteria [190]. Additionally, paraclinical
tests (e.g. Evoked Potentials tests) are executed to assess the probability of having MS [192–194]. Although MS is incurable, treatment is
available for patients to manage acute MS exacerbations and symptoms; also, disease-modifying drugs are available for patients with re-
current attacks [15,195–198]. Currently, therapeutic intention is to arrest disease activity and attain NEDA.
Understanding the disease could help in the management of its exacerbation. A general review of MS has pointed the environmental
and genetic susceptibility factors that could induce MS in patients. In regard, research on each susceptibility factor could help in under-
standing the reason for increased MS incidence and prevalence in Arabian Gulf countries. Knowledge of the triggers could help in expanding
the awareness in Arabian Gulf countries in an effort to minimise disease exacerbation.
Complex diseases develop from several factors – genetic, immunological and environmental – each with considerable effect on disease
development. Understanding the gene–immune–environment interactions can assist us in building new targeted therapies. Moreover, a
better understanding of these factors in Arabian Gulf Countries would help us in initiating new research on targeted therapy for citizens
of Arabian Gulf countries.
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